KIT and acute myeloid leukemia: We subdivided patients with t(8,21) AML into Caucasian and non-Caucasian subgroups, and the impact of KIT mutations on CR, relapse risk, and OS of the subgroups was analyzed separately based on the presence or absence of KIT mutations (Table 3).